Hematopoietic progenitor kinase 1
(HPK1), a hematopoietic cell-restricted
member of the serine/threonine Ste20-related protein kinases, is a
negative regulator of the T cell receptor, B cell receptor, and
dendritic cells. Loss of HPK1 kinase function increases cytokine secretion
and enhances T cell signaling, virus clearance, and tumor growth
inhibition. Therefore, HPK1 is considered a promising target for tumor
immunotherapy. Several HPK1 inhibitors have been reported to regulate
T cell function. In addition, HPK1-targeting PROTACs, which can
induce the degradation of HPK1, have also been developed. Here, we
provide an overview of research concerning HPK1 protein structure,
function, and inhibitors and propose perspectives and insights for
the future development of agents targeting HPK1.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.